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ABSTRACT
Germ cell tumors (GCT) arise from the cells that develop into sperms or eggs. They are commonly seen in testes and ovaries. Here, we 
report the case of a patient with bleomycin-induced lung injury (BILI) and dabigatran therapy for prior pulmonary thromboembolism 
underwent retroperitoneal lymph node dissection. The patient had dyspnoea and hypoxia during chemotherapy with a thrombus 
in the pulmonary artery and was managed with parenteral anticoagulation followed by dabigatran. He subsequently developed 
BILI and recovered. Dabigatran was stopped five days prior to surgery and perioperative anticoagulation bridged with dalteparin. 
Intraoperatively, we used inspired oxygen <35%, lung protective ventilation, goal-directed fluid therapy and intravenous morphine 
infusion. Postoperatively, we performed rectus sheath block and commenced transnasal humidified rapid insufflation ventilatory 
exchange. The patient had an uneventful recovery.
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Germ cell tumors (GCT) arise from the cells that develop into sperms or eggs. They are commonly seen in testes and ovaries. They represent the maximum life years 
lost per death among adult malignancies [1]. It has a response 
rate of 85% with the combined modality of chemotherapy with 
bleomycin, etoposide, and cisplatin (BEP) and retroperitoneal 
lymph node dissection (RPLND) surgery [2]. 
Here, we report a patient planned for RPLND with bleomycin-
induced lung injury (BILI) and who was on dabigatran for prior 
pulmonary thromboembolism. Anaesthetic management is 
complicated by the delicate balancing of fluid replacement with 
the loss while protecting against interstitial pulmonary edema, 
balancing anticoagulation with the need for surgical hemostasis, 
ensuring adequate analgesia sans epidural and optimizing 
perioperative patient oxygenation with minimal supplemental 
oxygen therapy. In view of these unique challenges, we present 
this case report. This report adheres to the CARE guideline [3].
CASE REPORT
A 19-year-old male, non-smoker, weighing 63kg with GCT 
of testis was posted for RPLND. He received 4 cycles of BEP 
chemotherapy. Subsequent to the first cycle, he developed 
dyspnoea and hypoxia. Thrombi in the inferior pulmonary artery 
and inferior vena cava (IVC) were identified in the Computerised 
Tomography (CT) imaging and he was started on low molecular 
weight heparin (LMWH) which was switched over to dabigatran. 
Five weeks following the fourth chemotherapy, he developed 
dyspnoea and desaturation.  BILI was diagnosed from CT chest 
showing bilateral patchy infiltrates and dramatic response to 
oral steroids which was continued and tapered over 6 weeks. 
Surgery was scheduled 4 months following last chemotherapy 
and 1 month after stopping steroids while the patient continued 
dabigatran 150mg twice a day (b.d.). The patient had no medical 
comorbidities. 
On examination, the pulse rate was 90/minute with a normal 
character, blood pressure was 130/84 mmHg, respiratory rate was 
16/minute and SpO2 in room air was 98%. Physical examination 
of the cardiovascular and respiratory system was unremarkable. 
Patient’s preoperative hemoglobin was 11.4 g%, blood urea 
was 28mg/dL and serum creatinine was 0.8 mg/dL. Creatinine 
clearance was 132 ml/minute. Liver function tests were normal. 
Echocardiogram was normal with an ejection fraction of 64%. 
Arterial blood gas analysis showed PaO2 of 95 mmHg in room 
air. Pulmonary function tests showed Forced expiratory volume 
in one second (FEV1) of 75%, Forced vital capacity (FVC) of 
63% and FEV1/FVC of 173% suggestive of restrictive disease. 
Perfusion scan showed multiple perfusion defects in both 
lungs probably due to interstitial infiltration. Ventilation scan was 
not feasible due to the patient’s inadequate efforts. The patient 
was assessed as American Society of Anaesthesiologists Physical 
Status (ASA-PS) III in view of BILI and was advised to stop 
dabigatran 5 days prior to surgery and started on dalteparin 5000 
Units subcutaneous b.d. therapy. Activated partial thromboplastin 
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time (aPTT) on day of surgery was 51 seconds (control 10-42 
seconds).
The patient was pre-oxygenated with air/oxygen at 40% 
inspired oxygen (FiO2), anesthesia induced with fentanyl  2 
ug/kg, propofol 2.5 mg/kg and vecuronium 0.1mg/kg was 
given for muscle relaxation. The trachea was intubated and 
the patient started on volume-controlled ventilation with tidal 
volume 375ml (6ml/kg ), respiratory rate 14/min, positive end-
expiratory pressure (PEEP) 8 cm-H2O, FiO2 35% and inspired 
airway pressure was maintained at 20-25mmHg by decreasing 
the pressure limit setting. 
Anesthesia was maintained with air/oxygen/sevoflurane. His 
heart rate, oxygen saturation (SpO2), electrocardiogram, intra-
arterial blood pressure, FiO2 and end-tidal oxygen concentrations, 
end-tidal carbon dioxide levels, minimum alveolar concentration, 
cardiac output, stroke volume, stroke volume variation (SVV), 
nasopharyngeal temperature, FloTrac/Vigeleo™ hemodynamic 
monitoring and hourly urine output was monitored. Analgesia 
was maintained with morphine 5mg Intravenous (IV) bolus 
followed by infusion at 1mg/hour with paracetamol 1gm IV. 
We used goal-directed fluid therapy (GDFT) targeting SVV 
<11. Ringer’s lactate was used as fluid replacement and blood 
loss was replaced with Gelofusine. Duration of surgery was 6.5 
hours and blood loss was 500 ml. The patient received 3000ml 
crystalloids and 500 ml Gelofusine. There were two brief episodes 
of hypotension concurrent with a rise in SVV which was managed 
with fluid boluses. Post-surgery, bilateral rectus sheath block was 
performed under ultrasound guidance with 0.25% bupivacaine 
40ml. 
Trachea was extubated after reversal and patient shifted to 
Intensive Care Unit (ICU) and connected to trans nasal humidified 
rapid insufflation ventilatory exchange (THRIVE) with AIRVO™ 
2 Optiflow nasal cannula (Fisher Paykel, Auckland, New 
Zealand) at FiO2 of 21%, temperature 37 C and flow rate of 35 
L/min. SpO2 was targeted at 90% which was maintained with the 
above settings. The patient was on morphine infusion at 0.5-1 mg/
hour for 3 days postoperatively. He did not require supplemental 
oxygen, was started on dalteparin 5000 subcutaneously b.d. from 
24 hours after surgery, was able to do incentive spirometry at 
1200 ml and bedside lung ultrasound showed minimal basal B 
lines. He was mobilized on day 3 and was restarted on dabigatran 
on day 5. The patient had an uneventful recovery. 
DISCUSSION
Restricted perioperative oxygen therapy is well known in the 
management of patients with BILI. The use of lung protective 
ventilation, goal-directed fluid therapy (GDFT) intra-operatively 
and use of THRIVE postoperatively in the management of BILI 
patients have not been reported before. 
The risk factors for development of BILI are genetic 
predisposition, cumulative dose >450 IU, age >70 years, bolus 
administration as compared to infusions, concomitant use of 
cisplatin and Granulocyte Colony Stimulating Factor (G-CSF), 
creatinine clearance (Cr Cl) <35ml/min, smoking and radiation 
therapy within 4 weeks of bleomycin exposure [4]. Evidence 
of pre-existing BILI or bleomycin exposure within 2 months 
are the major risk factors for BILI with hyperoxia exposure [5]. 
The mechanism of BILI is by increased pulmonary capillary 
permeability, necrosis of type 1 pneumocytes and increased 
macrophage migration which further recruits inflammatory cells 
and fibroblasts leading to pulmonary fibrosis [3]. Our patient 
developed BILI at a cumulative bleomycin dose of 360 IU, onset 
was at 11 weeks after bleomycin and concomitant G-CSF was 
another risk factor.
A 10-15% decrease in single breath diffusion capacity of the 
lung for carbon monoxide (DLCO) is the most sensitive indicator 
of subclinical damage. The restrictive ventilatory defect is the next 
common abnormality seen which was evident in our patient [5]. 
Positron Emission Tomography (PET) scan is a useful tool when 
faced with a dilemma as to initiate or continue treatment with 
anti-inflammatory agents as the uptake of 18-fluorodeoxyglucose 
is absent after successful immunosuppression [6]. GCT is not 
uncommonly associated with IVC thrombus. Due to rapid 
shrinkage of tumor cells during chemotherapy, there is a greater 
possibility of pulmonary thromboembolism. A high index of 
suspicion is required in patients with right-sided testicular 
tumors (due to direct draining of right gonadal vein into IVC) 
with paracaval abdominal mass >5cm in maximum transverse 
diameter meriting prophylactic anticoagulant therapy prior to, 
during and after chemotherapy [7]. 
Dabigatran is a directly acting thrombin inhibitor with peak 
plasma concentrations achieved at 1-2 hours and half-life (T ½) 
of 12-17 hours. In mild renal impairment- creatinine clearance 
(CrCl) 30-60 L/min T ½ is 15-18 hours and in severe renal 
impairment - CrCl <30 ml T ½ is 28 hours. Bridging with heparin 
may increase the bleeding risk and warfarin is a safer choice for 
bridging therapy. Idarucizumab is an antidote for dabigatran and 
useful in reversing anticoagulation in patients needing emergency 
surgery. It is given as 5gm IV dose through 2 consecutive 2.5 g 
infusions. Contraindications for dabigatran are CrCl <30 ml/min, 
patients with mechanical heart valves and pregnancy [8]. 
Testing for anticoagulant effect of dabigatran is indicated in 
moderate renal impairment, in the perioperative setting and in the 
event of bleeding. Thrombin time is very sensitive with linear dose-
response time and aPTT >80 seconds at trough drug level portends 
increased bleeding [8]. In patients with normal or mild renal 
dysfunction taken up for procedures with the potential for high 
risk of bleeding dabigatran is to be discontinued 48-72 hours prior 
to the procedure. For patients with Cr Cl 30-49 ml/min, it is to be 
discontinued 72-120 hours prior. Longer discontinuation is required 
in patients needing spinal or epidural catheter or port placement 
[10]. Preoperatively, bridging with heparin is only required in very 
high-risk thromboembolic patient and postoperative resumption is 
required between 48-72 hours after surgery.
RPLND is associated with large fluid shifts due to the extensive 
dissection of lymph nodes, large incision and prolonged duration 
of surgery making fluid management challenging in the setting of 
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pre-existing BILI. Post-operative pulmonary complications were 
associated with higher mean positive fluid balance (11.2 L vs. 
6.1 L, p=0.0001) and higher transfusion requirement (5.3±3.9 L 
vs. 1.24±1.6 L, p<0.0001) [11]. GDFT is useful in this setting. 
The epithelial-mesenchymal transition which is a precursor for 
fibro-proliferative changes in BILI was less in low tidal volume 
as compared to high tidal volume ventilator strategy [12]. Hence, 
we used lung protective ventilation.
Postoperatively, the patient was started on THRIVE as it 
generates higher pressures in the expiratory phase, resembles 
application of PEEP and thereby increases lung volume, prevents 
atelectasis, improves lung compliance and decreases dead space 
ventilation [13]. These benefits were achieved at FiO2 of 21% and 
helped prevent postoperative pulmonary morbidity. By utilizing 
technological advances such as goal-directed fluid management 
and THRIVE we ensured an uncomplicated recovery. We cannot 
generalize these recommendations based on a single case.
CONCLUSION
Restrictive perioperative oxygen therapy apart, the role of lung 
protective ventilation, goal-directed fluid therapy and THRIVE 
in the management of patients with BILI needs to be explored.
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